Literature DB >> 16883005

Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT.

Ron S Rosen1, Laura Fayad, Richard L Wahl.   

Abstract

UNLABELLED: We determined the prevalence of abnormal spinal 18F-FDG uptake and assessed the relationship between the severity of findings on 18F-FDG PET and the severity of degenerative spinal disease (DSD) on CT.
METHODS: PET/CT scans of 150 patients >18 y old, referred for whole-body 18F-FDG PET/CT for evaluation of known or suspected malignancy from June to July 2002, were analyzed retrospectively for the presence of increased 18F-FDG uptake in the spine and for anatomic correlates. Initially, PET images were examined and foci of 18F-FDG uptake in the spine were graded on a 0-4 scale based on intensity of 18F-FDG uptake (0 = definitely normal, 1 = probably normal, 2 = equivocal, 3 = probably abnormal, 4 = definitely abnormal). From PET alone, an impression as to whether lesions were most likely metastases or degenerative, as well the level of the spine involved, was also recorded. CT images of all 150 patients were reviewed independently by a musculoskeletal radiologist, who was unaware of patient identification, history, and findings of other imaging modalities, with the location recorded and severity graded on a 4-point-scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe for both degenerative disk and facet disease). The relationship between PET and CT findings was then determined.
RESULTS: Of the 150 patients, 63 (42.0%) had no abnormal findings in the spine on PET (grade 0), 27 (18.0%) had grade 1, 25 (16.7%) had grade 2, 17 (11.3%) had grade 3, and 16 patients (10.7%) had grade 4 18F-FDG uptake for DSD. Two additional patients had apparent spinal metastases with no degenerative changes. Five patients had metastases and DSD (included above). Of the patients who had abnormal spinal findings graded as probable or definite for DSD on CT (grades 3-4), 11 had abnormal findings in the cervical spine, 16 in the thoracic spine, and 23 patients in the lumbosacral spine. Seven patients (4.7%) had PET findings suggestive of spinal metastases. For patients with a maximum regional DSD score of 3, the mean 18F-FDG uptake for that spinal level was 1.4 +/- 1.5, whereas for patients with a maximum regional DSD score of 0, the mean PET grade was significantly lower at 0.4 +/- 0.9 (P = 0.0001).
CONCLUSION: Incidental findings on PET suggestive of DSD are common (22% of patients), most common in the lumbosacral spine, and can be recognized on CT. The severity of PET findings correlates with the severity of degenerative disk and facet disease as graded by CT, likely due to the fact that the inflammatory process that accompanies DSD is evident on PET. Increased 18F-FDG uptake in DSD should not be confused with metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883005

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Baastrup's disease (kissing spine) demonstrated by FDG PET/CT.

Authors:  Eugene Lin
Journal:  Skeletal Radiol       Date:  2007-11-16       Impact factor: 2.199

2.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

Review 3.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

4.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.

Authors:  Saima Muzahir; Robert Jeraj; Glenn Liu; Lance T Hall; Alejandro Munoz Del Rio; Timothy Perk; Christine Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

5.  Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.

Authors:  Motoho Morita; Tetsuya Higuchi; Arifudin Achmad; Azusa Tokue; Yukiko Arisaka; Yoshito Tsushima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-05       Impact factor: 9.236

6.  False-positive 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) findings of bone metastasis from esophagogastric cancer: report of two cases.

Authors:  Satoshi Ida; Masayuki Watanabe; Takanobu Yamao; Takatsugu Ishimoto; Yohei Nagai; Masaaki Iwatsuki; Yoshifumi Baba; Shirou Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Hideo Baba
Journal:  Surg Today       Date:  2014-06-07       Impact factor: 2.549

7.  18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters.

Authors:  Joyce C Mhlanga; John A Carrino; Martin Lodge; Hao Wang; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-19       Impact factor: 9.236

8.  Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults.

Authors:  Elena Lazzeri; Alessandro Bozzao; Maria Adriana Cataldo; Nicola Petrosillo; Luigi Manfrè; Andrej Trampuz; Alberto Signore; Mario Muto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-09       Impact factor: 9.236

Review 9.  Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections.

Authors:  Filip Gemmel; Paul C Rijk; James M P Collins; Thierry Parlevliet; Katrin D Stumpe; Christopher J Palestro
Journal:  Eur Spine J       Date:  2010-01-06       Impact factor: 3.134

10.  Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans.

Authors:  Molly A Parsons; Mateen Moghbel; Babak Saboury; Drew A Torigian; Thomas J Werner; Domenico Rubello; Sandip Basu; Abass Alavi
Journal:  Nucl Med Commun       Date:  2015-12       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.